Literature DB >> 15256761

Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.

Toshiro Niwa1, Yoshiko Yokota, Akira Tokunaga, Yasuhiro Yamato, Akira Kagayama, Tomoichi Fujiwara, Junko Hatakeyama, Masaharu Anezaki, Yuko Ohtsuka, Akira Takagi.   

Abstract

The tissue distribution after an intravenous dose of micafungin (1 mg/kg), a new echinocandin-like lipopeptide antifungal agent, to male rats was investigated. Micafungin in plasma disappeared biexponentially with a terminal half-life of 5.03 h. Micafungin concentrations in liver, kidney, and lung at the first sampling time (5 min) after dosing were 1.15, 1.64, and 2.58-fold higher than the plasma concentration, and the AUC(0- infinity ) were 1.61, 3.42, and 2.89-fold higher than that for plasma. The terminal half-lives for these tissues were 5.14, 4.87, and 5.31 h, respectively, which were comparable to those for plasma. These results suggest that micafungin distributes rapidly and moderately into tissues such as the liver, kidney, and lungs, and that the concentrations in tissues decreased in parallel with the unchanged drug in plasma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256761     DOI: 10.1248/bpb.27.1154

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  26 in total

1.  Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Authors:  David R Andes; Daniel K Reynolds; Scott A Van Wart; Alexander J Lepak; Laura L Kovanda; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

2.  Pharmacokinetics and tissue distribution of anidulafungin in rats.

Authors:  Bharat Damle; Martin Stogniew; James Dowell
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 3.  Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 5.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

6.  Micafungin treatment and eradication of candiduria among hospitalized patients.

Authors:  Steven Gabardi; Spencer Martin; Mihir Sura; Anisa Mohammed; Yoav Golan
Journal:  Int Urol Nephrol       Date:  2016-09-01       Impact factor: 2.370

7.  Intravenous injection of micafungin counteracts Candida albicans-induced aggravation of duodenal ulcers caused by cysteamine in rats.

Authors:  Tetsuya Nakamura; Masashi Yoshida; Yuko Kitagawa; Longxue Jin; Hideki Ishikawa; Kaori Kameyama; Go Wakabayashi; Minoru Tanabe; Shigeyuki Kawachi; Masahiro Shinoda; Yoshiro Saikawa; Norihito Wada; Tetsuro Kubota; Koichiro Kumai; Katsuko Sano; Masaki Kitajima
Journal:  Dig Dis Sci       Date:  2008-01-19       Impact factor: 3.199

8.  Initial characterization of micafungin pulmonary delivery via two different nebulizers and multivariate data analysis of aerosol mass distribution profiles.

Authors:  Shuai Shi; Elizabeth S Dodds Ashley; Barbara D Alexander; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2009-02-03       Impact factor: 3.246

9.  Penetration of micafungin into the burn eschar in patients with severe burns.

Authors:  Junichi Sasaki; Satoshi Yamanouchi; Yukio Sato; Shinya Abe; Yotaro Shinozawa; Satoshi Kishino; Naoki Aikawa; Shingo Hori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-15       Impact factor: 2.441

10.  Intraocular penetration of intravenous micafungin in inflamed human eyes.

Authors:  Kiyofumi Mochizuki; Akira Sawada; Shinsuke Suemori; Hideaki Kawakami; Yoshiaki Niwa; Yuji Kondo; Kiyofumi Ohkusu; Noriaki Yamada; Shinji Ogura; Takashi Yaguchi; Kazuko Nishimura; Satoshi Kishino
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.